Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease

JAMA

Volumn 305, Issue 2, 2011, Pages 160-166

  Tseng, Hung Fu ^a   Smith, Ning ^a   Harpaz, Rafael ^b   Bialek, Stephanie R ^b   Sy, Lina S ^a   Jacobsen, Steven J ^a  

^a KAISER PERMANENTE   (United States)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HERPES VACCINE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHRONIC DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HERPES ZOSTER; HOSPITALIZATION; HUMAN; IMMUNOCOMPETENCE; INCIDENCE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECIPIENT; RETROSPECTIVE STUDY; RISK REDUCTION; UNITED STATES;

EID: 78651505523     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2010.1983     Document Type: Article

References (36)

1. Dworkin RH, Johnson RW, Breuer J, et al. Recommendations for the management of herpes zoster. Clin Infect Dis. 2007;44(suppl 1):S1-S26.
2. Gnann JW Jr, Whitley RJ. Clinical practice: herpes zoster. N Engl J Med. 2002;347(5):340-346.
3. Thomas SL, Hall AJ. What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis. 2004;4(1):26-33.
4. Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LSA. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82(11):1341-1349.
5. Oxman MN, Levin MJ, Johnson GR, et al; Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271-2284.
6. Levin MJ, Oxman MN, Zhang JH, et al; Veterans Affairs Cooperative Studies Program Shingles Prevention Study Investigators. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis. 2008;197(6):825-835.
7. Harpaz R, Ortega-Sanchez IR, Seward JF; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWRRecomm Rep. 2008;57(rr-5):1-30, quiz CE2-CE4.
8. Clemens J, Brenner R, Rao M, Tafari N, Lowe C. Evaluating new vaccines for developing countries: efficacy or effectiveness? JAMA. 1996;275(5):390-397.
9. Orenstein WA, Bernier RH, Hinman AR. Assessing vaccine efficacy in the field: further observations. Epidemiol Rev. 1988;10:212-241. (Pubitemid 18262846)
10. Weinberg GA, Szilagyi PG. Vaccine epidemiology: efficacy, effectiveness, and the translational research roadmap. J Infect Dis. 2010;201(11):1607-1610.
11. Sy LS, Liu IL, Solano Z, et al. Accuracy of influenza vaccination status in a computer-based immunization tracking system of amanaged care organization. Vaccine. 2010;28(32):5254-5259.
12. Schiller JS, Euler GL. Vaccination coverage estimates from the National Health Interview Survey: United States, 2008. http://www.cdc.gov/nchs/data/ hestat/vaccine-coverage/vaccine-coverage.pdf. Accessed July 28, 2010.
13. Broome CV, Facklam RR, Fraser DW. Pneumococcal disease after pneumococcal vaccination: an alternative method to estimate the efficacy of pneumococcal vaccine. N Engl J Med. 1980;303(10):549-552.
14. Eurich DT, Marrie TJ, Johnstone J, Majumdar SR. Mortality reduction with influenza vaccine in patients with pneumonia outside "flu" season: pleiotropic benefits or residual confounding? Am J Respir Crit Care Med. 2008;178(5):527-533.
15. Jackson LA, Jackson ML, Nelson JC, Neuzil KM, Weiss NS. Evidence of bias in estimates of influenza vaccine effectiveness in seniors. Int J Epidemiol. 2006;35(2):337-344.
16. Leung J, Harpaz R, Molinari NM, Jumaan A. Herpes zoster incidence among insured persons in the United States, 1993-2006. Ann Intern Med. In Press.
17. Nelson JC, Jackson ML, Weiss NS, Jackson LA. New strategies are needed to improve the accuracy of influenza vaccine effectiveness estimates among seniors. J Clin Epidemiol. 2009;62(7):687-694.
18. Tate JE, Curns AT, Cortese MM, et al. Burden of acute gastroenteritis hospitalizations and emergency department visits in US children that is potentially preventable by rotavirus vaccination: a probe study using the now-withdrawn rotashield vaccine. Pediatrics. 2009;123(3):744-749.
19. Merck & Co. ZOSTAVAX (Zoster vaccine live): important information regarding storage and handling [package insert]. http://www.merck.com/product/ usa/pi-circulars/z/zostavax/zostavax-pi.pdf. Accessed June 15, 2010.
20. Lin F, Hadler JL. Epidemiology of primary varicella and herpes zoster hospitalizations: the prevaricella vaccine era. J Infect Dis. 2000;181(6):1897-1905. (Pubitemid 30416150)
21. Schmader K. Herpes zoster in the elderly: issues related to geriatrics. Clin Infect Dis. 1999;28(4):736-739. (Pubitemid 29169407)
22. Liesegang TJ. Herpes zoster ophthalmicus natural history, risk factors, clinical presentation, and morbidity. Ophthalmology. 2008;115(2)(suppl):S3-S12.
23. Severson EA, Baratz KH, Hodge DO, Burke JP. Herpes zoster ophthalmicus in Olmsted county, Minnesota: have systemic antivirals made a difference? Arch Ophthalmol. 2003;121(3):386-390.
24. Shaikh S, Ta CN. Evaluation and management of herpes zoster ophthalmicus. Am Fam Physician. 2002;66(9):1723-1730.
25. Schmader K, George LK, Burchett BM, Pieper CF. Racial and psychosocial risk factors for herpes zoster in the elderly. J Infect Dis. 1998;178(suppl 1):S67-S70.
26. Tseng HF, Smith N, Marcy SM, Sy LS, Chao CR, Jacobsen SJ. Risk factors of herpes zoster among children immunized with varicella vaccine: results from a nested case-control study. Pediatr Infect Dis J. 2010;29(3):205-208.
27. Lindley M. Zoster vaccine for adults 60 or older: do they know about it and do they want it? Paper presented at: 44th National Immunization Conference; April 19-22, 2010; Atlanta, GA.
28. Lu PJ, Euler GL, Jumaan AO, Harpaz R. Herpes zoster vaccination among adults aged 60 years or older in the United States, 2007: uptake of the first new vaccine to target seniors. Vaccine. 2009;27(6):882-887.
29. Okamoto S, Hata A, Sadaoka K, Yamanishi K, Mori Y. Comparison of varicella-zoster virus-specific immunity of patients with diabetes mellitus and healthy individuals. J Infect Dis. 2009;200(10):1606-1610.
30. Merck Research Laboratories. ZOSTAVAX - Zoster vaccine live (Oka/Merck): presented by Merck Research Laboratories at the Vaccines and Releated Biological Products Advisory Committee meeting of the Food and Drug Administration, December 15, 2005. http://www.fda.gov/ohrms/dockets/ac/05/slides/5-4198S2-2.ppt. Accessed July 28, 2010.
31. Donahue JG, Choo PW, Manson JE, Platt R. The incidence of herpes zoster. Arch Intern Med. 1995;155(15):1605-1609.
32. Jumaan AO, Yu O, Jackson LA, Bohlke K, Galil K, Seward JF. Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992-2002. J Infect Dis. 2005;191(12):2002-2007.
33. Mullooly JP, Riedlinger K, Chun C, Weinmann S, Houston H. Incidence of herpes zoster, 1997-2002. Epidemiol Infect. 2005;133(2):245-253.
34. Jackson LA, Reynolds MA, Harpaz R. Hospitalizations to treat herpes zoster in older adults: causes and validated rates. Clin Infect Dis. 2008;47(6):754-759.
35. Hicks LD, Cook-Norris RH, Mendoza N, Madkan V, Arora A, Tyring SK. Family history as a risk factor for herpes zoster: a case-control study. Arch Dermatol. 2008;144(5):603-608. (Pubitemid 351724420)
36. Hurley LP, Lindley MC, Harpaz R, et al. Barriers to the use of herpes zoster vaccine. Ann Intern Med. 2010;152(9):555-560.